Protein prognostic biomarkers in stage II colorectal cancer: implications for post-operative management

Aziz A. A. Alnakli, Abidali Mohamedali, Benjamin Heng, Charles Chan, Joo-Shik Shin, Michael Solomon, Pierre H. Chapuis, Gilles J. Guillemin, Mark S. Baker, Seong Beom Ahn*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

12 Downloads (Pure)


Colorectal cancer (CRC) poses a significant threat to many human lives worldwide and survival following resection is predominantly stage dependent. For early-stage cancer, patients are not routinely advised to undergo additional post-operative adjuvant chemotherapy. Acceptable clinical management guidelines are well established for patients in pTNM stages I, III and IV. However, recommendations for managing CRC stage II patients remain controversial and many studies have been conducted to segregate stage II patients into low- and high-risk of recurrence using genomic, transcriptomic and proteomic molecular markers. As proteins provide valuable insights into cellular functions and disease state and have a relatively easy translation to the clinic, this review aims to discuss potential prognostic protein biomarkers proposed for predicting tumour relapse in early-stage II CRC. It is suggested that a panel of markers may be more effective than a single marker and further evaluation is required to translate these into clinical practice.
Original languageEnglish
Article number13
Pages (from-to)1-10
Number of pages10
JournalBJC reports
Publication statusPublished - 13 Jan 2024

Bibliographical note

Copyright the Author(s) 2024. Version archived for private and non-commercial use with the permission of the author/s and according to publisher conditions. For further rights please contact the publisher.


Dive into the research topics of 'Protein prognostic biomarkers in stage II colorectal cancer: implications for post-operative management'. Together they form a unique fingerprint.

Cite this